Please login to the form below

Not currently logged in

Test reduces S. aureus mortality

AdvanDx has announced that a study of its PNA FISH test shows a significant reduction in mortality rates from Staphylococcus aureus bloodstream infections
AdvanDx has announced that a study of its PNA FISH test shows a significant reduction in mortality rates from Staphylococcus aureus (S. aureus) bloodstream infections.

Bloodstream infections due to Staphylococcus bacteria are a leading cause of hospital-acquired infection mortality. Conventional laboratory testing can take up to 48 hours to identify infection. This delay is necessary to ensure that a harmless skin bacteria hasn't affected patients results, and therefore making sure antibiotics are only prescribed to those infected with S. aureus.

The PNA FISH test identifies the presence of S. aureus in hours allowing clinicians to begin aggressive antibiotic treatment in infected patients far earlier.

The study, undertaken by clinicians in the Section of Infectious Diseases at Washington Hospital Center, showed the test was associated with an 82 per cent reduction in mortality rates from S.aureus infections in the intensive care unit (ICU) and a 53 per cent reduction in overall mortality from staphylococcal infections. The tests also showed a significant reduction in antibiotic use.

"We are very excited to see the results from the Washington Hospital Center study.  Not only do they show that rapid reporting of PNA FISH results can help significantly reduce unnecessary antibiotic use and improve patient care, but the rapid results also help to save lives," said Thais T Johansen, president and CEO of AdvanDx. 

More than 350,000 patients in the US contract bloodstream infections each year. Over 90,000 of these patients die. Rapid identification of the infecting bacterium is crucial in ensuring early treatment and saving lives.

15th July 2008


Featured jobs

Subscribe to our email news alerts


Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...